WO2022215568A1 - Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k - Google Patents

Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k Download PDF

Info

Publication number
WO2022215568A1
WO2022215568A1 PCT/JP2022/014842 JP2022014842W WO2022215568A1 WO 2022215568 A1 WO2022215568 A1 WO 2022215568A1 JP 2022014842 W JP2022014842 W JP 2022014842W WO 2022215568 A1 WO2022215568 A1 WO 2022215568A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipoteichoic acid
muscle
gram
acid
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/014842
Other languages
English (en)
Japanese (ja)
Inventor
大輔 河田
健 浮辺
泰幸 瀬戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Priority to JP2023512947A priority Critical patent/JPWO2022215568A1/ja
Publication of WO2022215568A1 publication Critical patent/WO2022215568A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the present invention relates to a muscle synthesis promoter for muscles.
  • the present invention also relates to promoters of p70S6K protein phosphorylation.
  • Muscles are essential organs for human physical movement. Since increasing muscle mass and strengthening muscle strength leads to improvement in athletic performance, it is a matter of great interest to people who play sports regardless of whether they are professionals or amateurs. Also, for people who do not usually exercise, maintaining and improving muscle mass is an important factor in maintaining good health and leading a smooth daily life.
  • Non-Patent Document 1 Whole-body muscle mass is maintained by a balance between muscle synthesis and muscle breakdown. Therefore, preventing muscle atrophy by promoting muscle synthesis and maintaining muscle mass are essential factors for extending healthy life expectancy and improving the QOL of the elderly. Even young people, for example, become temporarily bedridden due to injury or disease, and muscle atrophy easily progresses when the load on muscles decreases, adversely affecting rehabilitation and prognosis. Therefore, preventing muscle atrophy or maintaining muscle mass by promoting muscle synthesis will lead to improved QOL not only for the elderly but also for young people.
  • Patent Document 1 discloses that a physical activity promoter containing Lactobacillus gasseri strain OLL2809 as an active ingredient promotes physical activity and increases muscle mass.
  • Patent Document 2 discloses a lactobacillus strain of the genus Lactobacillus that promotes myoblast proliferation and muscle repair.
  • Patent Document 3 discloses that lipoteichoic acid derived from Lactobacillus carbatus CP2998 strain suppresses muscle degradation.
  • Patent document 1 increases muscle mass as a secondary effect associated with promotion of physical activity, but does not directly promote muscle synthesis.
  • Patent Document 2 also promotes muscle repair of damaged muscles, and does not promote muscle synthesis in a normal, undamaged state.
  • Patent Document 3 discloses that lipoteichoic acid is used as an active ingredient in the same manner as the present invention, but its effect is only to suppress muscle degradation and does not promote differentiation into skeletal muscle. Synthetic acceleration is not disclosed. Also, with regard to muscle degradation inhibition, only the action of lipoteichoic acid derived from a limited strain of lactic acid bacteria has been disclosed. Furthermore, the technique is disclosed as suppressing the degree of muscle breakdown when muscle breakdown is induced, and is intended for patients with advanced muscle atrophy. On the other hand, the present invention is different in that it is effective for muscle cells under normal conditions and is effective not only for sick people but also for healthy people.
  • the present invention is to provide a novel technique that contributes to promoting muscle synthesis and preventing muscle atrophy, characterized by directly promoting muscle synthesis without physical activity.
  • Muscle synthesis is promoted by activation of the Akt-mTOR (mechanistic target of rapamycin) pathway in muscle cells.
  • the p70S6K protein is downstream of the Akt-mTOR pathway and is activated by phosphorylation. Therefore, the amount of phosphorylated p70S6K is used as an indicator of activation of muscle synthesis, and an increase in the amount of phosphorylated p70S6K means activation of muscle synthesis.
  • the inventors have found that adding the cell wall of Gram-positive bacteria to muscle cells increases the amount of phosphorylated p70S6K in muscle cells and promotes muscle synthesis.
  • the present invention relates to the following inventions [1] to [8].
  • [1] A muscle synthesis promoter containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid as an active ingredient.
  • [2] The muscle synthesis promoter according to [1], wherein the lipoteichoic acid is derived from lactic acid bacteria or Bacillus subtilis, or the Gram-positive bacteria containing lipoteichoic acid is lactic acid bacteria or Bacillus subtilis.
  • the lipoteichoic acid is derived from a lactic acid bacterium belonging to the genus Lactobacillus or Bifidobacterium, or the Gram-positive bacterium containing lipoteichoic acid is a lactic acid bacterium belonging to the genus Lactobacillus or Bifidobacterium, [1] ] The muscle synthesis promoter described in ].
  • [6] A method of promoting muscle synthesis by causing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid to act on muscle cells, excluding medical procedures.
  • [7] A p70S6K protein phosphorylation promoter containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid as an active ingredient.
  • p70S6K according to [7], wherein the lactic acid bacterium from which lipoteichoic acid is derived is Lactobacillus gasseri or Lactobacillus delbrechskyi, or the lactic acid bacterium containing lipoteichoic acid is Lactobacillus gasseri or Lactobacillus delbrechskyi Promoter of protein phosphorylation.
  • Use of lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid for the production of a muscle synthesis promoter.
  • Lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid for use in promoting muscle synthesis.
  • a method for promoting muscle synthesis comprising ingesting or administering an effective amount of lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid to a subject in need thereof.
  • muscle synthesis is promoted by ingesting Gram-positive bacterial cell walls or lipoteichoic acid, or by directly acting lipoteichoic acid on muscle cells in vivo by a method such as intramuscular injection. can be made In addition, it is possible to increase the muscle mass of livestock by ingesting them as feed.
  • 1 is a photograph of Western blotting using an anti-lipoteichoic acid antibody on a fraction obtained in the process of purifying lipoteichoic acid from lactic acid bacteria.
  • a strong band was observed in the 25% and 35% propanol fractions, and in the 25% fraction of the extraction from Lactobacillus delbrecci, lipoteichoic acid was purified in this fraction.
  • 1 is a Western blot photograph and a quantitative graph showing that Gram-positive bacterial cell walls have an effect of promoting muscle synthesis in Test Example 1.
  • FIG. 1 is a Western blot photograph and a quantitative graph showing that a lipoteichoic acid-purified fraction of Lactobacillus gasseri has an effect of promoting muscle synthesis, according to Test Example 1.
  • FIG. 1 is a Western blot photograph and a quantitative graph showing that a lipoteichoic acid-purified fraction of Lactobacillus delbreeckii has an effect of promoting muscle synthesis, according to Test Example 1.
  • FIG. 2 is a Western blot photograph and a quantitative graph showing that Bacillus subtilis-derived lipoteichoic acid has an effect of promoting muscle synthesis in Test Example 2.
  • FIG. FIG. 10 is a Western blot photograph and a quantitative graph showing that the muscle synthesis-promoting effect is mediated by TLR2, according to Test Example 3.
  • the present invention provides a muscle synthesis promoter containing Gram-positive bacterial cell wall or lipoteichoic acid as an active ingredient.
  • a drug, food, drink, or feed containing gram-positive bacterial cell wall or lipoteichoic acid for promoting muscle synthesis or preventing muscle atrophy, and provide a method for promoting muscle synthesis by causing lipoteichoic acid to act on muscle cells.
  • Lipoteichoic acid is one of the cell wall constituents of Gram-positive bacteria and is generally included in Gram-positive bacteria. Moreover, not only the cell wall but also a part thereof is contained in the cell membrane. Lipoteichoic acid consists of long chains of glycerophosphate and ribitol phosphate. Since Gram-positive bacteria generally contain lipoteichoic acid, lipoteichoic acid can be obtained by extraction from suitable Gram-positive bacteria, and lipoteichoic acid derived from Bacillus subtilis is sold as a commercial reagent. In addition, lactic acid bacteria belong to Gram-positive bacteria. Therefore, it is possible to obtain inexpensive and safe lipoteichoic acid by extracting it from lactic acid bacteria that have been used in yogurt, lactic acid beverages, and the like and have been eaten.
  • the method for extracting and purifying lipoteichoic acid from Gram-positive bacteria is shown below.
  • the medium used for culturing the Gram-positive bacterium is not particularly limited as long as the bacterium can grow, and the bacterium can be cultured by a conventional method.
  • the cultured bacteria can be collected by a method such as centrifugation.
  • the obtained microbial cells may be used as they are, or the microbial cells subjected to concentration, drying, freeze-drying, and crushing treatment may be used. Cells killed by heat drying or the like can be used.
  • After extracting lipoteichoic acid from these cells using water, saline, organic solvents such as butanol, ethyl acetate, chloroform, or a mixture thereof, gel filtration chromatography, hydrophobic chromatography, etc. can be purified by
  • lactic acid bacteria belonging to the genus Lactobacillus or Bifidobacterium, or Bacillus subtilis are preferable, and lactic acid bacteria belonging to the genus Lactobacillus or Bifidobacterium are more preferable.
  • lactic acid bacteria belonging to the genus Lactobacillus include Lactobacillus acidophilus, Lactobacillus amylovorus, Lactobacillus gasseri, Lactobacillus delbrechky, Lactobacillus helveticus, Lactobacillus johnsonii, Lactobacillus paracasei, and Lactobacillus planus.
  • Lactic acid bacteria belonging to the genus Bifidobacterium include Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium breve, and Bifidobacterium.
  • Catenulatum Bifidobacterium mongoliense, Bifidobacterium pseudolongum, Bifidobacterium pseudocatenulatum, Bifidobacterium ficari or Bifidobacterium thermophilum are more preferred.
  • Most preferred Gram-positive bacteria are Lactobacillus gasseri SBT1848 (NITE-BP03075) or Lactobacillus delbreeckii SBT2002 (NITE-BP03280).
  • lipoteichoic acid lipoteichoic acid contained in Lactobacillus gasseri SBT1848 (NITE-BP03075) or Lactobacillus delbrecci SBT2002 (NITE-BP03280) is most preferable.
  • the muscle synthesis promoter of the present embodiment may contain lipoteichoic acid, and may be lipoteichoic acid extracted by the method described above, or may be a method using commercially available lipoteichoic acid.
  • a method of using Gram-positive bacteria as they are without performing extraction and purification as lipoteichoic acid may be used.
  • Gram-positive bacteria When Gram-positive bacteria are used as they are, the Gram-positive bacteria may be concentrated, dried, freeze-dried, or crushed, or killed by heat drying or the like. Therefore, it can be widely used as a composition contained in pharmaceuticals, quasi-drugs, food and drink, feed, and the like.
  • the muscle synthesis promoter of this embodiment can be in any form as long as the effects of the present invention can be obtained. That is, it may be in the form of fermented milk, or in other dosage forms.
  • Dosage forms include solid or powder formulations such as powders, fine granules, granules, tablets, capsules, and pills, and liquid formulations such as suspensions, emulsions, syrups, and extracts. can be mentioned.
  • the administration subject and the daily intake of the agent for preventing muscle atrophy according to the present embodiment are not particularly limited. It can be administered to elderly people, people under the age of 65, and the like. It can also be administered to subjects who have already developed locomotive syndrome or sarcopenia for treatment or alleviation, and can also be administered to healthy subjects who do not yet have such symptoms for prophylaxis.
  • the daily intake is also not particularly limited because it varies depending on age, symptoms, body weight, and purpose. 5g.
  • locomotive syndrome refers to the functional impairment of one or more locomotive organs such as bones, joints, cartilage, intervertebral discs, and muscles due to aging, resulting in decreased functions such as “standing” and “walking”. It means the state of being
  • sarcopenia refers to a syndrome characterized by age-related skeletal muscle atrophy, accompanied by a decrease in skeletal muscle mass and skeletal muscle strength, or a decrease in physical function.
  • the terms “promote muscle synthesis” or “promote muscle synthesis” refer to cases in which the agent for promoting muscle synthesis of the present invention is ingested by the subject, and cases in which the agent for promoting muscle synthesis of the present invention is not ingested by the subject. In comparison, it means that there is more synthesis of skeletal muscle. Whether “promoting muscle synthesis” or “promoting muscle synthesis” means that phosphorylation of the p70S6K protein is promoted when the active ingredient is administered to the subject, compared to the subject to which the active ingredient is not administered.
  • Examples of the myosynthesis promoter of the present invention include “maintain muscle”, “inhibit muscle atrophy”, “prevent muscle weakening”, “suppress muscle weakening”, “build muscle”, “ Increases muscle”, “builds muscle”, “promotes muscle synthesis”, “supports the ability to build muscle”, “helps prevent loss of muscle mass and strength”, “maintains muscle that declines with age” It is possible to display functions that are useful for” or that can be equated with these.
  • the above-mentioned “indication” includes everything that informs consumers of the above functions, and the object to be displayed is regardless of the medium such as the muscle synthesis promoter itself, packaging, containers, catalogs, pamphlets, and Internet homepages. .
  • p70S6K protein phosphorylation accelerator As used herein, "p70S6K protein” means the p70 ribosomal S6 kinase protein.
  • p70S6K p70 ribosomal protein S6 kinase
  • the p70S6K protein is downstream of the Akt-mTOR pathway and is activated by phosphorylation.
  • the p70S6K protein phosphorylation promoting agent of the present invention can be labeled with a function that is exhibited by promoting p70S6K protein phosphorylation.
  • the food or drink for promoting muscle synthesis or preventing muscle atrophy of the present invention may be any food or drink containing lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid, and may be general food or drink, or food for specified health use. , foods with function claims, dietary supplements, and supplements. Lactic acid beverages, cheese, yogurt and the like are examples of foods and drinks containing Gram-positive bacteria containing lipoteichoic acid.
  • Specific examples of the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention include carbonated drinks, various fruit juices, fruit juice drinks, soft drinks containing fruit juice, fruit drinks, fruit drinks containing fruit grains, and vegetables including various vegetables.
  • beverages soymilk/soymilk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, and other alcoholic beverages; caramel/candy, chewing gum, chocolate, cookies/biscuits, cakes/pies, snacks Confectionery such as crackers, Japanese confectionery, rice confectionery, bean confectionery, dessert confectionery; Butter, margarine, mayonnaise, vegetable oil and other fats and oils; Milk, processed milk, milk drinks, yogurts, lactic acid beverages, cheese, ice cream Milk and dairy products such as powdered milk, cream, processed agricultural products such as cereals (processed grains), baby food, and other commercially available foods such as liquid diet.
  • the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention may optionally contain antioxidants, flavoring agents, acidulants, coloring agents, emulsifiers, preservatives, seasonings, sweeteners, spices, pH adjusters, and stabilizers. agents, vegetable oils, animal oils, sugars and sugar alcohols, vitamins, organic acids, fruit juice extracts, vegetable extracts, grains, beans, vegetables, meats, seafood, and other additives and materials alone or in combination of two or more. can be blended together. The blending amounts of these materials and additives can be determined as appropriate.
  • the form of the food and drink for promoting muscle synthesis or preventing muscle atrophy of the present invention is not particularly limited. , semi-liquid, gel form, solid, bar, powder form.
  • the amount of lipoteichoic acid for promoting muscle synthesis or preventing muscle atrophy in these foods and drinks is not particularly limited because it varies depending on the form, dosage form, symptoms, body weight, application, etc. of the subject to be administered. It can be blended at, for example, 0.001 to 100 (w/w)%, 0.01 to 10 (w/w), or 0.1 to 1 (w/w)% on the basis of food and drink.
  • the above compounding amount is the compounding amount as lipoteichoic acid.
  • the feed for promoting muscle synthesis or preventing atrophy may be obtained by mixing the above-mentioned active ingredient with a normal feed, or by administering lipoteichoic acid or Gram-positive bacteria containing lipoteichoic acid.
  • the present embodiment can provide a novel muscle synthesis promoter.
  • This muscle synthesis accelerator contains lipoteichoic acid, which is generally contained in Gram-positive bacteria, as an active ingredient. If positive bacteria are used, highly safe products can be provided.
  • the mixture was separated into an aqueous layer, an intermediate layer and a butanol layer.
  • the aqueous layer was collected and the solvent was removed by lyophilization.
  • the resulting extract was dissolved in 5 mL of 15% propanol/0.1 M sodium acetate aqueous solution to obtain a crude lipoteichoic acid fraction.
  • the lipoteichoic acid crude fraction was then centrifuged and the supernatant filtered through a 0.22 ⁇ m filter.
  • a 1 mL Hitrap Octyl FF column (GE Healthcare) was equilibrated with a 15% propanol/sodium acetate aqueous solution, and 1 mL of the crude fraction supernatant was applied to the column.
  • lipoteichoic acid was purified to fractions eluted with 25% and 35% propanol/sodium acetate aqueous solutions in the extraction from Lactobacillus gasseri, and in the 25% fraction in the extraction from Lactobacillus delbrecci. (Fig. 1).
  • each fraction obtained in the process of lipoteichoic acid purification from lactic acid bacteria cell walls or strains was added.
  • the cells were washed with PBS and lysed using Alpha SureFire Ultra Lysis Buffer (PerkinElmer).
  • the cell lysate was collected and centrifuged to obtain the supernatant to obtain the sample for subsequent Western blotting.
  • Each sample was mixed with Laemmli sample buffer and heated at 90°C for 10 minutes for denaturation. The heated sample was applied to a 4-20% Criterion TGX gel (Bio-Rad) and electrophoresed at 200V constant pressure for 40 minutes.
  • the membrane was washed with TBST, immersed in HRP-labeled secondary antibody (Anti-rabbit IgG HRP-linked Antibody; Cell Signaling Technology) diluted 10,000 times with blocking buffer, and shaken for 1 hour. After secondary antibody reaction, the membrane was washed with TBST and reacted for 5 minutes using ECL Prime Western Blotting Detection Reagent or Clarity Max Western ECL Substrate (Bio-Rad). After completion of the reaction, signals were detected with Chemi Doc MP (Bio-Rad). After quantifying the signal intensity, the muscle synthesis promoting effect was evaluated by dividing the phosphorylated p70S6K value by the total p70S6K value.
  • HRP-labeled secondary antibody Anti-rabbit IgG HRP-linked Antibody; Cell Signaling Technology
  • propanol fractions which are purified fractions of lactic acid bacteria cell walls and lipoteichoic acid, were found to have muscle synthesis promoting activity (Figs. 2, 3 and 4). Since lipoteichoic acid is one of the cell wall constituents, it is contained in both the sediment (cell wall fraction) and the supernatant (soluble fraction) after centrifugation of the disrupted cells.
  • the control group was supplemented with the supernatant of the disrupted bacterial cells, which was found to have muscle synthesis-promoting activity. After recovering the cells, Western blotting was performed to evaluate the effect of promoting muscle synthesis. As a result, Bacillus subtilis-derived lipoteichoic acid was found to promote muscle synthesis at concentrations of 100 ng/mL or higher (Fig. 5).
  • TLR2 Toll-like receptor 2
  • TLR2 Toll-like receptor 2
  • muscle synthesis can be promoted or muscle atrophy can be prevented by Gram-positive bacterial cell walls or lipoteichoic acid.
  • muscle strength can be maintained and improved, healthy life expectancy can be extended, and QOL can be improved.
  • SBT1848 strain B Name and address of the depositary institution that deposited the biological material National Institute of Technology and Evaluation Patent Microorganism Depositary Center (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture (zip code 292-0818) ) Date of depositing the biological material at Roy's depository: November 25, 2019 (original date of deposit) September 10, 2021 (the date of transfer from the original deposit to the deposit under the Budapest Treaty) Accession number NITE BP-03075 assigned to the deposit by the depositary institution of Hai (2) SBT2002 strain A.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Le but de la présente invention est de fournir une nouvelle technique pour favoriser directement la synthèse musculaire sans activité physique et prévenir l'atrophie musculaire.　L'invention concerne : un agent favorisant la synthèse musculaire ou un agent de prévention de l'atrophie musculaire contenant une paroi cellulaire bactérienne à gram positif ou un acide lipotéichoïque en tant que principe actif; ou un procédé pour favoriser la synthèse musculaire en permettant à une paroi cellulaire bactérienne à gram positif ou à un acide lipotéichoïque d'agir sur des cellules musculaires.
PCT/JP2022/014842 2021-04-08 2022-03-28 Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k Ceased WO2022215568A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023512947A JPWO2022215568A1 (fr) 2021-04-08 2022-03-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021065572 2021-04-08
JP2021-065572 2021-04-08

Publications (1)

Publication Number Publication Date
WO2022215568A1 true WO2022215568A1 (fr) 2022-10-13

Family

ID=83545422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/014842 Ceased WO2022215568A1 (fr) 2021-04-08 2022-03-28 Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k

Country Status (3)

Country Link
JP (1) JPWO2022215568A1 (fr)
TW (1) TW202304470A (fr)
WO (1) WO2022215568A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502456A (ja) * 2009-08-26 2013-01-24 アールエヌエー アイエヌシー リポタイコ酸由来の糖脂質及びこれを含む組成物
JP2013047192A (ja) * 2011-08-29 2013-03-07 Meiji Co Ltd 身体活動を促進させる乳酸菌
WO2015068809A1 (fr) * 2013-11-07 2015-05-14 サントリーホールディングス株式会社 Agent d'amélioration de la fonction de barrière intestinale contenant un ferment lactique
JP2018083761A (ja) * 2016-11-21 2018-05-31 アサヒグループホールディングス株式会社 筋肉の分解抑制剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019230957A1 (fr) * 2018-06-01 2019-12-05 雪印メグミルク株式会社 Composition pour accélérer la réparation musculaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502456A (ja) * 2009-08-26 2013-01-24 アールエヌエー アイエヌシー リポタイコ酸由来の糖脂質及びこれを含む組成物
JP2013047192A (ja) * 2011-08-29 2013-03-07 Meiji Co Ltd 身体活動を促進させる乳酸菌
WO2015068809A1 (fr) * 2013-11-07 2015-05-14 サントリーホールディングス株式会社 Agent d'amélioration de la fonction de barrière intestinale contenant un ferment lactique
JP2018083761A (ja) * 2016-11-21 2018-05-31 アサヒグループホールディングス株式会社 筋肉の分解抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AISO, CHISATO: "Effects of Lactococcus lactis subsp. cremoris FC-fermented milk on muscle mass and protein metabolism signaling in aged mice", THE JOURNAL OF PHYSICAL FITNESS AND SPORTS MEDICINE, vol. 9, no. 6, 25 November 2020 (2020-11-25), pages 305, XP009535208, ISSN: 2186-8131 *
SIJTSMA L, WOUTERS J T, HELLINGWERF K J: "Isolation and characterization of lipoteichoic acid, a cell envelope component involved in preventing phage adsorption, from Lactococcus lactis subsp. cremoris SK110", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 172, no. 12, 1 December 1990 (1990-12-01), US , pages 7126 - 7130, XP055976557, ISSN: 0021-9193, DOI: 10.1128/jb.172.12.7126-7130.1990 *

Also Published As

Publication number Publication date
TW202304470A (zh) 2023-02-01
JPWO2022215568A1 (fr) 2022-10-13

Similar Documents

Publication Publication Date Title
Lau et al. Probiotics: Health benefits, food application, and colonization in the human gastrointestinal tract
AU2019243093B2 (en) Nutritional composition, food/drink composition using nutritional composition, and modified milk powder using nutritional composition
US8501169B2 (en) Microorganisms for improving the health of individuals with disorders related to gluten ingestion
KR102224072B1 (ko) 면역 조절능력과 혈중콜레스테롤 감소 능력이 모두 뛰어난 비피도박테리엄 롱검 아종 균주 및 이의 용도
Xiao et al. Lactic acid bacteria in health and disease
US11607435B2 (en) Probiotics Bifidobacteria strains
NO327792B1 (no) Bifidobakteriumstamme, formulering omfattende nevnte stamme, og anvendelse derav i matprodukter eller medikamenter ved behandling av sykdom.
CA2824619A1 (fr) Bifidobacterium cect 7765 et son utilisation pour prevenir et/ou traiter le surpoids, l'obesite et les pathologies associees
SG177743A1 (en) Novel lactobacillus plantarum and composition comprising same
JP6923883B2 (ja) 栄養状態改善に使用するための組成物
JP7791828B2 (ja) 筋委縮予防剤
CN105121627A (zh) 含有乳杆菌属菌的组合物
JP2018177703A (ja) Ｔｏｌｌ様受容体２活性化用組成物
KR20240118626A (ko) 락티플란티바실러스 플란타럼 y7 균주를 포함하는 장 기능 개선용 조성물
WO2020116511A1 (fr) Composition servant à la suppression d'une infection au norovirus
JP5950993B2 (ja) 迷走神経活性化剤
WO2022215568A1 (fr) Agent favorisant la synthèse musculaire et agent favorisant la phosphorylation de la protéine p70s6k
AU2017287987B2 (en) Cartilage regeneration facilitating composition
WO2017057307A1 (fr) Élément de contrôle de production d'anticorps
Lavermicocca et al. Table olives: a carrier for delivering probiotic bacteria to humans
WO2021151956A1 (fr) Composition pour le traitement de maladies intestinales ou pulmonaires
JP7849997B2 (ja) Ｉａｐ活性化用組成物
Ibrahim et al. Dietary modulation of gut microbiota by cultured products
US12599641B2 (en) Probiotic composition for improving soy protein proteolysis and amino acid production activity
US20220387522A1 (en) Composition for enhancing or improving immune system comprising bifidobacterium bifidum

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22784553

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023512947

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22784553

Country of ref document: EP

Kind code of ref document: A1